Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

1-25 of 45 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Targeting chromosomal instability in patients with cancer.
Al-Rawi DH, Lettera E, Li J, DiBona M, Bakhoum SF
Nat Rev Clin Oncol, 21(9):645-659, 11 Jul 2024
Cited by: 2 articles | PMID: 38992122
Add to export list Review
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow.
Becht R, Kiełbowski K, Wasilewicz MP
Int J Mol Sci, 25(3):1456, 25 Jan 2024
Cited by: 4 articles | PMID: 38338736 | PMCID: PMC10855889
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma.
Caputo WL, de Souza MC, Basso CR, Pedrosa VA, Seiva FRF
Cancers (Basel), 15(23):5653, 30 Nov 2023
Cited by: 1 article | PMID: 38067357 | PMCID: PMC10705715
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.
Ng CKY, Dazert E, Boldanova T, Coto-Llerena M, Nuciforo S, Ercan C, Suslov A, Meier MA, Bock T, Schmidt A, Ketterer S, Wang X, Wieland S, Matter MS, Colombi M, Piscuoglio S, Terracciano LM, Hall MN, Heim MH
Nat Commun, 13(1):2436, 04 May 2022
Cited by: 44 articles | PMID: 35508466 | PMCID: PMC9068765
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.
Ho CM, Lin KT, Shen R, Gu DL, Lee SS, Su WH, Jou YS
Comput Struct Biotechnol J, 20:1752-1763, 09 Apr 2022
Cited by: 2 articles | PMID: 35495118 | PMCID: PMC9024375
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL, Wang KH, Hsieh HP, Yen WC
J Biomed Sci, 29(1):5, 21 Jan 2022
Cited by: 8 articles | PMID: 35062934 | PMCID: PMC8781143
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma.
Qiao Y, Pei Y, Luo M, Rajasekaran M, Hui KM, Chen J
Exp Biol Med (Maywood), 246(12):1343-1354, 25 Apr 2021
Cited by: 3 articles | PMID: 33899543 | PMCID: PMC8243214
Add to export list Review Free full text in Europe PMC
Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
Borah NA, Reddy MM
Molecules, 26(7):1981, 01 Apr 2021
Cited by: 59 articles | PMID: 33915740 | PMCID: PMC8037052
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC.
Cheng C, Wu X, Shen Y, Li Q
Cancer Manag Res, 12:13241-13257, 23 Dec 2020
Cited by: 15 articles | PMID: 33380832 | PMCID: PMC7767722
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
New landscapes and horizons in hepatocellular carcinoma therapy.
Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA
Aging (Albany NY), 12(3):3053-3094, 04 Feb 2020
Cited by: 31 articles | PMID: 32018226 | PMCID: PMC7041742
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway.
Shen ZT, Chen Y, Huang GC, Zhu XX, Wang R, Chen LB
BMC Cancer, 19(1):1075, 08 Nov 2019
Cited by: 21 articles | PMID: 31703572 | PMCID: PMC6842208
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
DNA hypermethylation of aurora kinase A in hepatitis C virus‑positive hepatocellular carcinoma.
Ma Z, Liu Y, Hao Z, Hua X, Li W
Mol Med Rep, 20(3):2519-2532, 11 Jul 2019
Cited by: 6 articles | PMID: 31322223 | PMCID: PMC6691273
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression.
Ryu J, Pyo J, Lee CW, Kim JE
Cancer Med, 7(11):5589-5603, 17 Sep 2018
Cited by: 7 articles | PMID: 30221846 | PMCID: PMC6246935
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor.
Zhu Q, Yu X, Zhou ZW, Luo M, Zhou C, He ZX, Chen Y, Zhou SF
J Cancer, 9(12):2061-2071, 24 May 2018
Cited by: 7 articles | PMID: 29937924 | PMCID: PMC6010685
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib.
Gavriilidis P, Poutahidis T, Giakoustidis A, Makedou K, Angelopoulou K, Hardas A, Andreani P, Zacharioudaki A, Saridis G, Gargavanis A, Louri E, Antoniadis N, Karampela E, Psychalakis N, Michalopoulos A, Papalois A, Iliadis S, Mudan S, Azoulay D, Giakoustidis D
J Cancer, 9(5):914-922, 27 Feb 2018
Cited by: 2 articles | PMID: 29581770 | PMCID: PMC5868156
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
HepG2 and human healthy hepatocyte in vitro culture and co-culture in PCL electrospun platforms.
Fasolino I, Guarino V, Marrese M, Cirillo V, Vallifuoco M, Tamma ML, Vassallo V, Bracco A, Calise F, Ambrosio L
Biomed Mater, 13(1):015017, 20 Dec 2017
Cited by: 10 articles | PMID: 28901955
Add to export list
Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.
Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, Liang D, Lei H, Subrata S, Kelley KW, Lam EW, Jin B, Liu Q
Med Res Rev, 36(6):1036-1079, 13 Jul 2016
Cited by: 131 articles | PMID: 27406026
Add to export list Review
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG
Oncotarget, 7(31):50290-50301, 01 Aug 2016
Cited by: 19 articles | PMID: 27385211 | PMCID: PMC5226583
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Multi-kinase inhibitors, AURKs and cancer.
Cicenas J, Cicenas E
Med Oncol, 33(5):43, 01 Apr 2016
Cited by: 26 articles | PMID: 27038473
Add to export list Review
Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition.
Fan Y, Lu H, Ma H, Feng F, Hu X, Zhang Q, Wang J, Xu Y, Zhao Q
Food Funct, 6(12):3746-3759, 01 Dec 2015
Cited by: 8 articles | PMID: 26369427
Add to export list
Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.
Zi D, Zhou ZW, Yang YJ, Huang L, Zhou ZL, He SM, He ZX, Zhou SF
Int J Mol Sci, 16(11):27228-27251, 13 Nov 2015
Cited by: 37 articles | PMID: 26580601 | PMCID: PMC4661876
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review.
Gavriilidis P, Giakoustidis A, Giakoustidis D
J Clin Med Res, 7(10):742-751, 23 Aug 2015
Cited by: 30 articles | PMID: 26345296 | PMCID: PMC4554212
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Aurora kinase A in gastrointestinal cancers: time to target.
Katsha A, Belkhiri A, Goff L, El-Rifai W
Mol Cancer, 14:106, 20 May 2015
Cited by: 58 articles | PMID: 25987188 | PMCID: PMC4436812
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE
Haematologica, 100(7):898-904, 17 Apr 2015
Cited by: 31 articles | PMID: 25887498 | PMCID: PMC4486224
Add to export list Free full text in Europe PMC
The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP, Yang YX, Liu QL, Zhou ZW, Pan ST, He ZX, Zhang X, Yang T, Pan SY, Duan W, He SM, Chen XW, Qiu JX, Zhou SF
Drug Des Devel Ther, 9:1027-1062, 17 Feb 2015
Cited by: 24 articles | PMID: 25733818 | PMCID: PMC4338784
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 45 results

1 2

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

Targeting chromosomal instability in patients with cancer.

New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow.

Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma.

Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.

Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma.

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.

KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC.

New landscapes and horizons in hepatocellular carcinoma therapy.

Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway.

DNA hypermethylation of aurora kinase A in hepatitis C virus‑positive hepatocellular carcinoma.

An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression.

A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor.

Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib.

HepG2 and human healthy hepatocyte in vitro culture and co-culture in PCL electrospun platforms.

Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Multi-kinase inhibitors, AURKs and cancer.

Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition.

Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review.

Aurora kinase A in gastrointestinal cancers: time to target.

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.

The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.

Partnerships & funding